344 related articles for article (PubMed ID: 27405060)
1. Hepatic B cell leukemia-3 promotes hepatic steatosis and inflammation through insulin-sensitive metabolic transcription factors.
Gehrke N; Wörns MA; Huber Y; Hess M; Straub BK; Hövelmeyer N; Waisman A; Kim YO; Schuppan D; Galle PR; Schattenberg JM
J Hepatol; 2016 Dec; 65(6):1188-1197. PubMed ID: 27405060
[TBL] [Abstract][Full Text] [Related]
2. Formononetin promotes fatty acid β-oxidation to treat non-alcoholic steatohepatitis through SIRT1/PGC-1α/PPARα pathway.
Liao J; Xie X; Wang N; Wang Y; Zhao J; Chen F; Qu F; Wen W; Miao J; Cui H
Phytomedicine; 2024 Feb; 124():155285. PubMed ID: 38185065
[TBL] [Abstract][Full Text] [Related]
3. The hepatocyte IKK:NF-κB axis promotes liver steatosis by stimulating de novo lipogenesis and cholesterol synthesis.
Heida A; Gruben N; Catrysse L; Koehorst M; Koster M; Kloosterhuis NJ; Gerding A; Havinga R; Bloks VW; Bongiovanni L; Wolters JC; van Dijk T; van Loo G; de Bruin A; Kuipers F; Koonen DPY; van de Sluis B
Mol Metab; 2021 Dec; 54():101349. PubMed ID: 34626855
[TBL] [Abstract][Full Text] [Related]
4. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis.
Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB
Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855
[TBL] [Abstract][Full Text] [Related]
5. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease.
Li X; Wang Z; Klaunig JE
Toxicology; 2018 Dec; 410():199-213. PubMed ID: 30120929
[TBL] [Abstract][Full Text] [Related]
6. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
Serviddio G; Bellanti F; Vendemiale G
Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
8. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1α regulation in vitro and in vivo.
Park MJ; Kim DI; Lim SK; Choi JH; Kim JC; Yoon KC; Lee JB; Lee JH; Han HJ; Choi IP; Kim HC; Park SH
J Hepatol; 2014 Nov; 61(5):1151-7. PubMed ID: 25003952
[TBL] [Abstract][Full Text] [Related]
9. Human germline hedgehog pathway mutations predispose to fatty liver.
Guillen-Sacoto MJ; Martinez AF; Abe Y; Kruszka P; Weiss K; Everson JL; Bataller R; Kleiner DE; Ward JM; Sulik KK; Lipinski RJ; Solomon BD; Muenke M
J Hepatol; 2017 Oct; 67(4):809-817. PubMed ID: 28645738
[TBL] [Abstract][Full Text] [Related]
10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
11. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK
World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482
[TBL] [Abstract][Full Text] [Related]
12. Suppression of NF-κB activation by PDLIM2 restrains hepatic lipogenesis and inflammation in high fat diet induced mice.
Hao YR; Tang FJ; Zhang X; Wang H
Biochem Biophys Res Commun; 2018 Sep; 503(2):564-571. PubMed ID: 29852170
[TBL] [Abstract][Full Text] [Related]
13. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
14. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
[TBL] [Abstract][Full Text] [Related]
15. The role of hepassocin in the development of non-alcoholic fatty liver disease.
Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte vitamin D receptor regulates lipid metabolism and mediates experimental diet-induced steatosis.
Bozic M; Guzmán C; Benet M; Sánchez-Campos S; García-Monzón C; Gari E; Gatius S; Valdivielso JM; Jover R
J Hepatol; 2016 Oct; 65(4):748-757. PubMed ID: 27245430
[TBL] [Abstract][Full Text] [Related]
17. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
Cong WN; Tao RY; Tian JY; Liu GT; Ye F
Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
[TBL] [Abstract][Full Text] [Related]
18. A nonalcoholic fatty liver disease model in human induced pluripotent stem cell-derived hepatocytes, created by endoplasmic reticulum stress-induced steatosis.
Parafati M; Kirby RJ; Khorasanizadeh S; Rastinejad F; Malany S
Dis Model Mech; 2018 Sep; 11(9):. PubMed ID: 30254132
[TBL] [Abstract][Full Text] [Related]
19. The ameliorating effect of withaferin A on high-fat diet-induced non-alcoholic fatty liver disease by acting as an LXR/FXR dual receptor activator.
Shiragannavar VD; Sannappa Gowda NG; Puttahanumantharayappa LD; Karunakara SH; Bhat S; Prasad SK; Kumar DP; Santhekadur PK
Front Pharmacol; 2023; 14():1135952. PubMed ID: 36909161
[No Abstract] [Full Text] [Related]
20. Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model.
Orime K; Shirakawa J; Togashi Y; Tajima K; Inoue H; Nagashima Y; Terauchi Y
Eur J Pharmacol; 2016 Feb; 772():22-32. PubMed ID: 26724391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
